NeoGraph Analytics
Specialty PharmaceuticalsNorth America2023 – 2032

US Compounding Pharmacy Market Size, Share and Trends Analysis

US compounding pharmacy market analysis shows $25.8B valuation in 2023, projected to grow at 6.8% CAGR to $48.2B by 2032. Explore market trends, segmentation, and key players.

Revenue, 2023

$25.8B

Forecast, 2032

$48.2B

CAGR, 2024-2032

6.8%

Report Coverage

North America

Code: us-compounding-pharmacy-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Market Overview

The US compounding pharmacy market, valued at $25.8 billion in 2023, is experiencing steady growth driven by personalized medicine demand and regulatory advancements, with projections indicating a $48.2 billion market by 2032.

Market Stage

Early growth

Adoption Level

Growing

Key Trends

Rise of personalized medicineAI-driven formulation optimizationIncreased focus on sterile compoundingRegulatory consolidation under DQSA
02

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 6.8%

Base Year (2023)

$27.6B

Forecast (2032)

$48.2B

CAGR (2024-2032)

6.8%

Regional Market Analysis
Market share and growth rate by region

North America

#1
Share: 65.0%CAGR: 6.5%

Largest market: United States

Europe

#2
Share: 20.3%CAGR: 5.8%

Largest market: Germany

03

Market Dynamics

  • Aging population requiring specialized dosages
  • Rising prevalence of chronic diseases
  • Advancements in biotechnology enabling complex formulations
  • Growth of niche therapeutic areas like oncology
04

Market Segmentation

By Application

  • Oncology
  • Dermatology
  • Pain Management
  • Pediatrics
  • Ophthalmology

By End User

  • Hospitals
  • Retail Pharmacies
  • Long-Term Care Facilities
  • Ambulatory Care Centers
05

Regional Analysis

1

North America

Lead: United States
CAGR: 6.5%Share: 65.0%

Dominates the global market due to advanced healthcare infrastructure and strong demand for personalized therapies.

2

Europe

Lead: Germany
CAGR: 5.8%Share: 20.3%

Stable growth driven by increasing regulatory harmonization and adoption of compounding in oncology.

3

Asia Pacific

Lead: Japan
CAGR: 7.2%Share: 14.7%

Emerging market with rapid adoption of automated compounding systems in urban healthcare centers.

Country-Level Analysis

CountryShareGrowth
United States
60.2%
+6.7%
Germany
12.4%
+5.5%
United Kingdom
9.8%
+5.3%
06

Competitive Landscape

C

CVS Health

US

Leader150B

Integrated pharmacy services with extensive retail and hospital compounding capabilities

AI Formulation AssistantAutomated Sterile Compounding System
W

Walgreens Boots Alliance

US

Leader

Major retail pharmacy chain with nationwide compounding network and AI-driven formulation tools

A

Apotheca

US

Challenger1.2B

Specialized in sterile compounding for oncology and critical care with robotic systems

OncoCompounding AISterile Process Optimizer
H

Healthpointe Pharmacy

US

Follower

Focuses on non-sterile compounding for dermatology and pain management

B

Baxter International

US

Challenger20.5B

Advanced sterile compounding solutions with FDA-approved automated systems

SteriFlow AIIV Safety Monitoring System
07

Recent Developments

25
2025CVS Health

Launched AI-powered compounding platform for personalized pain management formulations

24
2024Walgreens

Acquired 3 regional compounding pharmacies to expand sterile compounding capacity

24
2024Apotheca

Secured FDA approval for robotic sterile compounding system in oncology settings

23
2023Baxter

Introduced blockchain tracking for compounded IV medications in 100+ hospitals

23
2023Pharmacy Compounding Center

Developed 3D-printed hormone replacement therapies for pediatric patients

08

Regulatory Landscape

Drug Quality and Security Act (DQSA) of 2013FDA's Current Good Manufacturing Practices (cGMP) for CompoundingState-specific Pharmacy Practice Acts with varying compounding requirements
09

Frequently Asked Questions

The US compounding pharmacy market was valued at $25.8 billion in 2023 and is projected to reach $48.2 billion by 2032.
The market is expected to grow at a compound annual growth rate (CAGR) of 6.8% from 2024 to 2032.
Sterile compounding represents the largest segment with 35.2% market share, driven by high demand in hospital settings.
Major growth drivers include the aging population requiring specialized dosages, rising chronic disease prevalence, advancements in biotechnology, and the expansion of personalized medicine applications.